1123-P: Analysis of Readmissions for Diabetic Ketoacidosis in Patients with Hidradenitis Suppurativa: A Nationwide Analysis

Hidradenitis suppurativa (HS) is known to increase the risk of diabetes mellitus. This study aims to compare rates and outcomes of 30-day readmissions following admissions for type 1 diabetic ketoacidosis (T1DKA) in patients with and without co-existing Hidradenitis Suppurative (HS) in the United States. We analyzed the 2018 National Readmission Database. We included index hospitalizations for all patients (aged≥18 years) with a principal diagnosis of T1DKA using ICD-10 codes. We further sub-stratified this group into those with and with a secondary diagnosis of HS. Chi-square tests and regression analysis were used to compare rates and outcomes of 30-day readmissions between both groups. We excluded elective and traumatic readmissions. A total of 94,461 index hospitalizations for T1DKA, that were discharged alive, were included in the analysis. 109 (0.2%) of these, had co-existing HS. A total of 15,614 (16.5%) readmissions occurred within 30 days. Readmission rates were similar between HS and non-HS group (21.8% vs. 16.5%, p=0.328). HS group had a similar mean hospital length of stay (3.0 days vs. 2.9 days, p=0.645) and mean total hospital costs ($6,878 vs. $7,236, p=0.691) compared to the non-HS group. Readmissions for T1DKA in HS patients were associated with a total of 331 hospital days and $747,976 in hospital costs. T1DKA without coma was the most common reason for readmission in both groups. HS patients admitted for T1DKA have a greater, but statistically non-significant rate of 30-day readmission, and similar readmission outcomes compared to non-HS patients admitted for TIDKA. Disclosure E. Edigin: None. H. Shaka: None. P. O. Eseaton: None. M. Almani: None. A. Kichloo: None. P. E. Ojemolon: None. D. Jakhar: None.